Home / Search / Parkinson's Disease

Parkinson's Disease

Second most common neurodegenerative disease. Loss of dopaminergic neurons causes motor symptoms. Glymphatic dysfunction identified as a precursor to alpha-synuclein accumulation, opening an early-intervention research window.

Search Parkinson's Disease evidence →
612
Papers (5yr)
9
Active trials
4
Tracked biomarkers
3
Related diseases
Research signals

Glymphatic clearance research in Parkinson's has grown 78% over 5 years. Alpha-synuclein immunotherapy is in Phase II/III across multiple sponsors. View full research signals ->

Tracked biomarkers
NfL (CSF)Strong evidence

Universal neuronal damage marker. Tracks disease progression across multiple trials.

Alpha-synuclein (CSF)Strong evidence

Direct pathology marker. Used as target engagement marker for immunotherapy trials.

DAT-SPECT imagingModerate evidence

Dopamine transporter imaging. Confirms nigrostriatal degeneration in early diagnosis.

IL-6/TNF-aModerate evidence

Neuroinflammatory cytokines shared with ALS and Alzheimer's research.

Active clinical trials
NCT IDDrugPhaseStatusSponsor
NCT05019273Glymphatic enhancementPhase IIRecruitingStanford University
NCT04780867PrasinezumabPhase IIbActiveRoche/Prothena

View all ALS trials in platform →

Related diseases — shared mechanisms

Phase 1 primary cohort + monitored diseases

Alzheimer's
Shared: glymphatic clearance
ALS
Shared: microglial activation
MS
Shared: neuroinflammation
Research and educational use only. Information does not constitute medical advice, diagnosis, or treatment recommendations. Verify with primary literature. AI disclaimer →